Gilead Sciences

We deliver innovation that changes the trajectory of serious diseases. Fast Company named Gilead as the #1 Most Innovative Company in Medicines, Therapeutics and Pharmaceuticals for 2026, recognizing our twice‑yearly HIV prevention medicine as a breakthrough of our innovative manufacturing and distribution practices enabling availability and access where it’s most needed. This achievement is powered by our extraordinary teams, whose work turns science into hope and possibility for people around the world. https://gilead.inc/3Nyhl59

Today we’re spotlighting the manufacturing work behind our twice-yearly HIV prevention medication. Manufacturing often happens behind the scenes, but it can contribute as much to the transformative power of medicine as research or clinical development. From overcoming complex chemistry challenges to designing production and supply strategies with global access in mind, some of the most important decisions happen years before a medicine ever reaches patients. Hear from Stacey Ma, Gilead’s EVP and Head of Pharmaceutical Development & Manufacturing, as she explains how nearly two decades of high-stakes problem-solving, cutting edge science and cross-functional teamwork helped pave the way for a new approach to HIV prevention medication development: https://gilead.inc/3PKwaSB

Athena Jones is a powerful voice in the #breastcancer community, sharing her lived experience and challenging the status quo for women navigating treatment decisions for aggressive cancers like metastatic triple-negative breast cancer (mTNBC).      This #TNBCAwarenessMonth, watch to learn about common misconceptions surrounding #mTNBC. 

#GileadNews: We have entered into a definitive agreement to acquire Ouro Medicines, a privately held biotechnology company focused on developing T cell engager therapies for autoimmune diseases. The acquisition adds OM336, a clinical‑stage BCMAxCD3 T cell engager, to Gilead’s growing inflammation portfolio and underscores our commitment to advancing transformative therapies for people living with serious autoimmune diseases. Read more: https://lnkd.in/gQzaNmPj

Today, we have the privilege of introducing René Bennett, a California native who developed her leadership skills as a hardworking first-generation college graduate, university commencement speaker and practicing lawyer, before stepping into her current role as a Director of FOCUS at Gilead Sciences. A Hurricane Katrina survivor and published policy advocate, René recognized early on the urgent need to expand health care access and meet people where they’re at. She remains deeply committed to advancing equitable health care, working across global systems, collaborating with industry leaders and connecting directly with health care providers and communities impacted by policy decisions.

We’re honored to share that Gilead has been recognized by Ethisphere as one of the 2026 World’s Most Ethical Companies® This designation reflects ongoing work to embed ethics and integrity as a core principle in how we operate and make decisions. It acknowledges sustained and focused efforts to strengthen our ethics and compliance programs and foster a culture grounded in accountability and trust. We’re grateful to the many teams across Gilead whose commitment contributes to the culture this recognition represents. #WorldsMostEthicalCompanies #EthicsInAction

At #SXSW this weekend, we brought together voices from music, medicine and media for an important conversation on #HIV prevention and #PrEP. The discussion featured Grammy Award–winning artist Ciara, HIV specialist Leo Moore, MD, MSHPM, AAHIVE, DipIBLM, media personality Loren LoRosa and Gilead’s Jenny Yun. When science and culture come together, they can help make HIV prevention more visible, more relatable and easier to talk about. Expanding awareness starts with open dialogue, meeting communities where they are and helping more people understand their prevention options. Photos by Daniel Boczarski/Getty Images for Gilead Sciences

At Gilead, we always put patients first – that’s why our clinical research team pursued a more challenging crossover clinical trial for those living with metastatic triple-negative breast cancer (mTNBC) – the most aggressive form. Read more at https://lnkd.in/g8HC57B4.

#GileadNews: We’re pleased to share that following publication in NEJM, our Phase 3 ASCENT-04 results have since been updated by the National Comprehensive Cancer Network® (NCCN®)'s Clinical Practice Guidelines in Oncology (NCCN Guidelines®) as a Category 1 preferred regimen for certain people living with metastatic #TNBC. Learn more about why this is important for patients and the community: https://gilead.inc/418N1Rs

The next medical breakthrough could be created right now in our labs. With $32 billion committed to U.S. innovation, we're not just investing in the future, we're creating it. Every investment, every hire, every new facility creates new possibilities for therapies that will transform lives. U.S. innovation is making the medicines of the future. Are you ready to be part of creating what’s next? Learn more: https://gilead.inc/4blWmdw #FutureOfMedicine #CreatingPossible #TransformingLives